Sign up Australia
Proactive Investors - Run By Investors For Investors

Daily CryptoCann Report: Buffett and Gates have harsh words for Bitcoin; Marijuana Index on the decline

It's not the first time the Oracle of Omaha's comments have spooked cryptocurrency investors
Crypto coins
EOS was the only cryptocurrency not in the red

Four of the top five cryptocurrencies were in the red Monday after comments from multibillionaires Warren Buffett and Bill Gates.

Prior to Berkshire Hathaway’s annual meeting, Buffett described Bitcoin as “probably rat poison squared” and said that it will never produce any value for investors.

Bill Gates told CNBC that he would short Bitcoin if he could. He called cryptocurrencies “crazy, speculative things” and said that cryptocurrency investing is “a pure ‘greater fool theory’ type of investment.”

READ: Daily CryptoCann Report: Bitcoin heist suspect escapes; new East Coast dispensaries to open

EOS was the only cryptocurrency to rise, recovering from last week’s downward streak.

Bitcoin Cash (BCH-USD) was the top decliner, down more than 6% to US$1,641.39.

Ethereum (ETH-USD) was the second-largest decliner, down nearly 6% to US$744.88.

Ripple (XRP-USD) fell more than 4% to US$0.83 while Bitcoin (BTC-USD) was down nearly 3% to US$9,383.47.

The North American Marijuana Index, comprised of the leading cannabis stocks in the US and Canada, fell more than 1%.

Medical cannabis company Sunniva Inc (OTCQX:SNNVF) saw a share boost after announcing the site of its Canadian facility. The Vancouver-based company has selected a 126-acre zone in Okanagan Falls, British Columbia, as part of a $7 million agreement. Shares were up less than 1% to US$6.84.

Research and development company Scythian Biosciences Corp (OTCQB:SCCYF) entered into an agreement with cannabis company Isodiol International Inc (OTCMKTS:ISOLF)  to import Isodiol products throughout the Caribbean as well as Central and South America. Scythian Biosciences develops treatments and preventions for concussions and traumatic brain injuries through cannabinoid-based drugs. The Toronto-based company also invested $2 million into Isodiol. Shares of Scythian were down nearly 5% to US$3.07 while shares of Isodiol were also down around 5% to US$0.56.

View full ISOL profile View Profile

Isodiol International Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use